The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Visual abstract | Key updates to the classification of MDS in the 5th WHO Classification of Haematolymphoid Tumours
The MDS Hub is pleased to present a visual abstract summarizing the key updates and changes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Updates include the grouping of myelodysplastic syndromes (MDS) entities as genetically or morphologically defined and the addition of MDS-SF3B1, MDS-5q, and MDS-biTP53 as genetically defined subtypes. Terminology describing the types of childhood MDS have been revised and the diagnostic criteria for chronic myelomonocytic leukemia have been amended.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content